The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 29 rounds in the feed, most often in Biotech.
Venture capitalorbimed.comRounds from 2018-01-29 to 2026-10-28
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Dren Bio A privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases | Funding round Verified against 4 of 199 sources | $350M | 2026-10-28 | [ PART ] |
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Funding round |
| $200M |
| 2026-10-22 |
| [ LEAD ] |
Altis Labs An AI platform for cancer trials | Series A Verified against 4 of 7 sources | $25M | 2026-09-17 | [ LEAD ] |
TytoCare The remote examination company is shifting focus from low-acuity primary care toward cardiopulmonary and oncology support | Growth Verified against 6 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $25M | 2026-07-15 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Crossover financing Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-05-04 | [ LEAD ] |
Pulnovo Medical Pulnovomed develops and conducts clinical trials for innovative treatments in pulmonary hypertension and heart failure, specifically focusing on pulmonary artery denervation technology. | Funding round Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-04-19 | [ PART ] |
Terremoto Cutting-edge small-molecule therapies for cancer and other diseases targeted primarily at healthcare providers and researchers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $108M | 2026-04-15 | [ PART ] |
Sidewinder Therapeutics Sidewinder Therapeutics specializes in developing bispecific antibody-drug conjugates aimed at treating difficult cancers for patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $137M | 2026-04-08 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $250M | 2026-01-12 | [ PART ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-11-20 | [ LEAD ] |
ELECTRA Therapeutics Electra Therapeutics develops SIRP-directed therapies designed to improve outcomes for patients with immune-mediated diseases and cancer. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $183M | 2025-10-22 | [ PART ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D+ Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $38M | 2025-05-22 | [ PART ] |
Curevo Curevo Inc. develops an adjuvanted subunit vaccine for the prevention of shingles in adults. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2025-03-17 | [ PART ] |
Pulnovo Medical Pulnovomed develops and conducts clinical trials for innovative treatments in pulmonary hypertension and heart failure, specifically focusing on pulmonary artery denervation technology. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-03-02 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-01-10 | [ LEAD ] |
Verdiva Bio Verdiva Bio develops next-generation medicines aimed at treating obesity and cardiometabolic diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $411M | 2025-01-09 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $400M | 2024-03-21 | [ PART ] |
Terremoto Cutting-edge small-molecule therapies for cancer and other diseases targeted primarily at healthcare providers and researchers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $175M | 2023-11-02 | [ PART ] |
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Series C Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $90M | 2023-09-05 | [ PART ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2023-08-23 | [ PART ] |
Odyssey Odyssey Therapeutics develops innovative therapies aimed at transforming the treatment of autoimmune and inflammatory diseases for patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $168M | 2022-10-13 | [ PART ] |
Terremoto Cutting-edge small-molecule therapies for cancer and other diseases targeted primarily at healthcare providers and researchers. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2022-05-25 | [ LEAD ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $147.5M | 2022-05-09 | [ PART ] |
ELECTRA Therapeutics Electra Therapeutics develops SIRP-directed therapies designed to improve outcomes for patients with immune-mediated diseases and cancer. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $84M | 2022-02-16 | [ LEAD ] |
Insilico Medicine AI-powered drug discovery and development tools to pharmaceutical companies and researchers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $255M | 2021-06-22 | [ PART ] |
Caris Life Sciences Caris Life Sciences sells precision oncology solutions including molecular profiling tests and data analytics for cancer detection and treatment. | Growth Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $830M | 2021-05-11 | [ PART ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2020-04-01 | [ LEAD ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Seed Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $6.5M | ~ 2019-12-12 | [ PART ] |
TytoCare The remote examination company is shifting focus from low-acuity primary care toward cardiopulmonary and oncology support | Series C Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $25M | 2018-01-29 | [ PART ] |